Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

Eli Lilly and Company (NYSE: LLY) shares are trading lower Tuesday. The stock appears to be moving in reaction to an ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Analysts appear to be crushing hard on Eli Lilly, with 18 out of 21 giving it a “Buy” rating, despite its sky-high valuation.

ProQR Therapeutics N.V.’s PRQR share price has dipped by 5.53%, which has investors questioning if this is right time to buy.

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Analysts were rushing to reiterate their conviction in the stock following Thursday’s blow to Zepbound and Lilly shares.

Eli Lilly’s LLY first-quarter revenue grew 45%, as combined sales for Mounjaro (diabetes) and Zepbound (obesity) rose ...